ASCORBIC ACID ( DrugBank: Ascorbic acid )
4 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 10 | シャルコー・マリー・トゥース病 | 7 |
| 97 | 潰瘍性大腸炎 | 2 |
| 206 | 脆弱Ｘ症候群 | 2 |
| 298 | 遺伝性膵炎 | 1 |
10. シャルコー・マリー・トゥース病
臨床試験数 : 41 / 薬物数 : 46 - (DrugBank : 9) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 15
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs031190109 | 25/10/2019 | 03/10/2019 | Ascorbic acid treatment for childhood Charcot-Marie-Tooth disease 1A | Ascorbic acid treatment for childhood Charcot-Marie-Tooth disease 1A - Ascorbic acid for CMT1A | Charcot-Marie-Tooth disease type 1A CMT1A;G600 | ascorbic acid dayly intake | SHIOHAMA TADASHI | NULL | Recruiting | Not applicable | < 18age old | Both | 12 | Phase 2 | Japan |
| 2 | JPRN-UMIN000036332 | 2019/06/15 | 28/03/2019 | Ascorbic acid treatment for Charcot-Marie-Tooth disease type 1A | Ascorbic acid treatment for Charcot-Marie-Tooth disease type 1A - Ascorbic acid treatment for CMT1A | Charcot-Marie-Tooth diease type 1A | Ascorbic acid treatment: 20mg/kg/day, dayly | Chiba University | NULL | Pending | 1years-old | Not applicable | Male and Female | 10 | Phase 1 | Japan |
| 3 | NCT00484510 (ClinicalTrials.gov) | April 2007 | 8/6/2007 | High Dose Ascorbic Acid Treatment of CMT1A | A Randomized, Placebo-controlled, Double Masked 120 Subject Futility Design Clinical Trial of Ascorbic Acid Treatment of Charcot Marie Tooth Disease Type 1A. | Charcot-Marie-Tooth Disease, Type Ia | Drug: Ascorbic acid (Vitamin C);Drug: placebo | Wayne State University | Muscular Dystrophy Association;Charcot-Marie-Tooth Association | Completed | 13 Years | 70 Years | Both | 110 | Phase 2/Phase 3 | United States |
| 4 | NCT00271635 (ClinicalTrials.gov) | January 2006 | 3/1/2006 | Ascorbic Acid Treatment in CMT1A Trial (AATIC) | Phase 2 Study of Ascorbic Acid Treatment in Charcot-Marie-Tooth Type 1A | Charcot-Marie-Tooth Disease;Hereditary Motor and Sensory Neuropathies | Drug: Placebo;Drug: ascorbic acid | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | NULL | Completed | 12 Years | 25 Years | Both | 13 | Phase 2 | Netherlands |
| 5 | EUCTR2006-000032-27-IT (EUCTR) | 19/10/2005 | 14/03/2006 | MULTICENTRE RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF LONG-TERM ASCORBIC ACID TREATMENT IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A CMT-TRIAAL CMT-TRial Italian with Ascorbic Acid Long term - CMT-TRIAAL | MULTICENTRE RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF LONG-TERM ASCORBIC ACID TREATMENT IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A CMT-TRIAAL CMT-TRial Italian with Ascorbic Acid Long term - CMT-TRIAAL | Charcot-Marie-Tooth disease type 1A CMT1A MedDRA version: 6.1;Level: HLGT;Classification code 10034606 | Trade Name: CEBION 500MG 20CPR MAST.ARAN INN or Proposed INN: ACIDO ASCORBICO DC.IT INN or Proposed INN: SODIO ASCORBATO DC.IT | ISTITUTO NEUROLOGICO CARLO BESTA | NULL | Not Recruiting | Female: yes Male: yes | 202 | Italy | |||
| 6 | JPRN-UMIN000001535 | 2005/04/01 | 01/01/2009 | A multicenter, randomized open trial of ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A | A multicenter, randomized open trial of ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A - CMT-AA | Charcot-Marie-Tooth disease 1A | Ascorbic acid (AA) treatment group (12 weeks oral AA (20mg/kg/day) no AA treatment group | New treatment strategies for intractable neuropathies based on its pathomechanism.The Research Grant 19A-5 for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare. | NULL | Complete: follow-up complete | 15years-old | 75years-old | Male and Female | 60 | Phase 1,2 | Japan |
| 7 | EUCTR2004-004501-24-IT (EUCTR) | 22/12/2004 | 13/02/2007 | Multicentre, randomised, double blind, placebo controlled trial of ascorbic acid treatment in Charcot-Marie-Tooth Disease Type 1A CMT1A . | Multicentre, randomised, double blind, placebo controlled trial of ascorbic acid treatment in Charcot-Marie-Tooth Disease Type 1A CMT1A . | Charcot-Marie-Tooth Disease Type 1A CMT1A . MedDRA version: 6.1;Level: HLT;Classification code 10022031 | Trade Name: CEBION 500*20CPR MAST 500MG Product Name: ACIDO ASCORBICO INN or Proposed INN: Ascorbic acid vit C | ISTITUTO NEUROLOGICO CARLO BESTA | NULL | Not Recruiting | Female: yes Male: yes | 200 | Italy |
97. 潰瘍性大腸炎
臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03581149 (ClinicalTrials.gov) | March 26, 2018 | 27/3/2018 | Tolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acid in Ulcerative Colitis Patients | Tolerability and Efficacy of Low-Volume Sodium Picosulfate/Magnesium Citrate Versus 2L Polyethylene Glycol/Ascorbic Acid in Patients With Ulcerative Colitis Undergoing Colonoscopy: A Randomized Controlled Trial | Ulcerative Colitis | Drug: Sodium Picosulfate/Magnesium Citrate Laxative;Drug: 2L polyethylene glycol/ascorbic acid | American University of Beirut Medical Center | NULL | Recruiting | 18 Years | 65 Years | All | 68 | Phase 4 | Lebanon |
| 2 | NCT01929668 (ClinicalTrials.gov) | August 2013 | 23/8/2013 | Comparison of 4L Polyethylene Glycol and 2L Polyethylene Glycol With Ascorbic Acid in Inactive UC Patients | Comparison of 4L Polyethylene Glycol and 2L Polyethylene Glycol With Ascorbic Acid in Patients With Inactive Ulcerative Colitis; Randomized, Single Blind, Multicenter Study | Ulcerative Colitis | Drug: polyethylene glycol;Drug: Ascorbic Acid | Kyungpook National University | NULL | Completed | 18 Years | 80 Years | Both | 114 | N/A | Korea, Republic of |
206. 脆弱Ｘ症候群
臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-005460-42-ES (EUCTR) | 07/07/2016 | 20/04/2016 | Clinical trial to evaluate ascorbic acid (vitamin C) and tocopherol (vitamin E) in combination versus placebo for the treatment of cognitive and behavioral disorders in children with fragile x syndrome | Phase III clinical trial, double-blind, cross-way, to evaluate the safety and efficacy ascorbic acid (vitamin C) and tocopherol (vitamin E) combination versus placebo for the treatment of cognitive and behavioral disorders in children with fragile x syndrome | Fragile x syndrome MedDRA version: 19.0;Level: PT;Classification code 10017324;Term: Fragile X syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Vitamin C INN or Proposed INN: Vitamin C Other descriptive name: ACIDUM ASCORBICUM D6 Product Name: Vitamin E INN or Proposed INN: Vitamin E Other descriptive name: TOCOPHERYL ACETATE | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | NULL | Not Recruiting | Female: no Male: yes | Phase 3 | Spain | |||
| 2 | NCT01329770 (ClinicalTrials.gov) | December 2010 | 29/3/2011 | Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome | Phase II Double-blind Randomized Placebo-controlled 1-way Crossover Trial to Investigate Safety and Efficacy of the Ascorbic Acid and Tocopherol for the Treatment of the Fragile X Syndrome | Fragile X Syndrome | Dietary Supplement: Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E);Dietary Supplement: Placebo | Yolanda de Diego Otero | NULL | Completed | 6 Years | 18 Years | Male | 30 | Phase 2 | Spain |
298. 遺伝性膵炎
臨床試験数 : 95 / 薬物数 : 148 - (DrugBank : 51) / 標的遺伝子数 : 53 - 標的パスウェイ数 : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2006-000087-83-GB (EUCTR) | 19/12/2008 | 04/12/2007 | EUROPAC2 trial to investigate the efficacy of ANTOX(vers) 1.2 and MGCT (magnesiocard) for the treatment of hereditary pancreatitis and idiopathic chronic pancreatitis. - EUROPAC2 | EUROPAC2 trial to investigate the efficacy of ANTOX(vers) 1.2 and MGCT (magnesiocard) for the treatment of hereditary pancreatitis and idiopathic chronic pancreatitis. - EUROPAC2 | Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis MedDRA version: 13.1;Level: HLT;Classification code 10033646;Term: Acute and chronic pancreatitis;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 13.1;Level: PT;Classification code 10056976;Term: Hereditary pancreatitis;System Organ Class: 10010331 - Congenital, familial and genetic disorders | Trade Name: Magnesiocard 2.5mmol Other descriptive name: MAGNESIUM ASPARTATE HYDROCHLORIDE Product Name: ANTOX (vers) 1.2 Product Code: ANTOX Other descriptive name: TOCOPHEROL INN or Proposed INN: ASCORBIC ACID Other descriptive name: SELENIUM INN or Proposed INN: METHIONINE | University of Liverpool | The Royal Liverpool and Broadgreen University Hospitals NHS Trust | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 240 | Phase 3 | United Kingdom |